Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$8.59 - $20.77 $431,973 - $1.04 Million
-50,288 Closed
0 $0
Q1 2022

May 11, 2022

BUY
$15.52 - $35.65 $67,527 - $155,113
4,351 Added 9.47%
50,288 $951,000
Q4 2021

Feb 08, 2022

BUY
$28.89 - $35.33 $41,283 - $50,486
1,429 Added 3.21%
45,937 $1.61 Million
Q3 2021

Nov 02, 2021

BUY
$35.66 - $42.94 $143,388 - $172,661
4,021 Added 9.93%
44,508 $1.63 Million
Q2 2021

Aug 11, 2021

BUY
$23.7 - $39.27 $620,063 - $1.03 Million
26,163 Added 182.65%
40,487 $1.59 Million
Q1 2021

May 14, 2021

BUY
$27.01 - $36.8 $34,923 - $47,582
1,293 Added 9.92%
14,324 $405,000
Q4 2020

Feb 12, 2021

BUY
$27.51 - $34.36 $24,566 - $30,683
893 Added 7.36%
13,031 $417,000
Q3 2020

Nov 04, 2020

BUY
$25.8 - $34.61 $30,727 - $41,220
1,191 Added 10.88%
12,138 $392,000
Q2 2020

Jul 28, 2020

BUY
$17.65 - $28.05 $193,214 - $307,063
10,947 New
10,947 $302,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.75B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.